Brought to you by 
Gradalis raises $24mm through Series B round for cancer vaccine development
31 Jan 2013
Executive Summary
Gradalis Inc. (formerly Murex Pharmaceuticals; developing personalized cancer vaccines) has raised $24mm through its Series B round from new and returning private and institutional investors. The company had originally planned to raise $10mm.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Gradalis raises $24mm through Series B round for cancer vaccine development
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice